Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

Marqibo upon successful completion of rALLy and mark another in a series of milestone achievements in recent months that underscore our ability to execute in terms of product development."

"These exciting data bring us another step closer to making this promising treatment available to this very sick ALL patient population for whom there are currently no approved or standard therapies," stated Anne Hagey, M.D., vice president and chief medical officer. "Marqibo may enable high-potency dosing of vincristine chemotherapy and improve efficacy versus standard vincristine without increased toxicity."

Yesterday, Hana Biosciences announced the findings from a planned, pre-specified safety review of data from the rALLy trial conducted by an Independent Data Monitoring Committee (IDMC). The IDMC meeting outcome supports an acceptable, manageable safety profile for Marqibo with no new safety concerns. The IDMC has recommended that the trial continue to completion per the protocol. The Company has now accrued greater than 75 percent (43 patients) of the total target enrollment of 56 patients and recruitment is on target to complete by mid-2009.

The primary objective of the rALLy study is to assess the efficacy of single-agent, weekly Marqibo (2.25 mg/m2) with dosing based on actual body surface area without the dose capping applied to standard vincristine. Secondary objectives include evaluation of safety, response duration, and survival. The patient population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation. The rALLy trial is currently being conducted at thirty-one clinical sites in the U.S., Canada, Germany, Israel and the United Kingdom.

Hana Biosciences has received orphan drug and fast track designations for Marq
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PINE BROOK, N.J. , Sept. 22, 2014 ... developing antibody therapies to treat infectious disease, today ... adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab ... of inhalational anthrax and data from these studies ... when administered intravenously (IV) at the intended therapeutic ...
(Date:9/22/2014)...  AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), ... machines, announced today that they are starting production of ... unit is designed for placement inside optical shops and ... statistics, there are over 20,000 optical stores in ... world,s first automated kiosk dedicated to cleaning and sanitizing ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... Pevion Biotech AG today announced ... therapeutic Candida vaccine PEV7, demonstrating the generation of specific ... Furthermore, the results again confirm the capability of Pevion,s ... long-lasting immunity in humans against otherwise weak antigens ...
... Mass. and MIAMI, Jan. 16, 2012 Boston Scientific ... endpoint data from its ORION trial, demonstrating excellent outcomes ... patients with iliac artery disease, a form of peripheral ... insufficient blood flow.  Results were presented today by Daniel ...
Cached Medicine Technology:Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 2Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5
(Date:9/23/2014)... Angeles, CA (PRWEB) September 23, 2014 ... power score of 3.7 out of 5, indicating ... fixed or portable and range from basic household ... of reading gas concentrations in parts per million. ... them the choice of many suppliers, especially amongst ...
(Date:9/23/2014)... NJ (PRWEB) September 23, 2014 With ... cease the sale of all tobacco products, retail chains ... products and services to patients, customers, and shoppers. In ... the stakeholders of retail pharmacy healthcare to share their ... you need to know to coordinate care with other ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dallas-based luxury linen ... appointment of Leslie Eades as vice president of product development. ... as well as the primary lead on global sourcing for ... head of both the product development group and sourcing group ... team. , Eades notes, "Peacock Alley is a brand ...
(Date:9/22/2014)... FL (PRWEB) September 23, 2014 ... wrinkles. A Sublime Beauty® cream helps to relax ... boost collagen levels and hydrate beautifully. , "Our ... a multi-tasker for aging skin," says Kathy Heshelow, ... as the natural botox, wrinkles are relaxed while ...
(Date:9/22/2014)... September 23, 2014 Recently, BamboofloorChina.com, an ... new range of solid bamboo floors . According ... are now provided at discounted rates, up to 30 ... until September 30. , BamboofloorChina.com is ... solid bamboo floors are made according to the newest ...
Breaking Medicine News(10 mins):Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Luxury Linen Purveyor Peacock Alley Announces New Vice President of Product Development 2Health News:How to Reduce Wrinkles and Improve Aging Skin from Sublime Beauty®; One Day Sale on Now 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... may soon impact the quality of patient care for ... report. ,Without intervention, the number of allergy-immunology ... demand will increase by 35 percent over the next ... ,The decline in the number of qualified allergists-immunologists ...
... today warned consumers could be seriously misled by proposed new ... to Food Standards Australia and New Zealand (FSANZ), Dr Yong ... confuse consumers and may even contribute to unhealthy diets. ... on labels to encourage consumers to buy their products, Dr ...
... insensitive caption for the picture of an abandoned baby in Melbourne ... left in a cardboard box kept by a Japanese hospital for ... Jikei Hospital in the southern city of Kumamoto to discourage abortions ... ,A small hatch on the side of the hospital has ...
... This high degree of trust and confidence in doctors reflects ... survey reflects the immense efforts from doctors to improve ... the financial pressures placed upon the health service. ... this survey, the majority of respondents have answered that doctors ...
... University of Illinois food science and human nutrition professor ... a persons diet , and safe alternatives to hormone-replacement ... spent a decade evaluating the health effects of isoflavones, ... in soy. Much of his work has focused on ...
... of Wisconsin-Madison have designed a powerful analytical tool capable of ... moving proteins in mid-fold and see the shapes of intermediate ... is that the first applications of the technique offer a ... is implicated in type II diabetes. ,Pancreatic ...
Cached Medicine News:Health News:America on Brink of Allergy Crisis 2Health News:Three-year-old Abandoned in Box Meant for Unwanted Babies in Japan 2Health News:Soy Products a Double-edged Sword for Breast Cancer 2Health News:Soy Products a Double-edged Sword for Breast Cancer 3Health News:New Analytical Tool to Unravel the Cause of Diabetes 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: